Journal Scans
Neoadjuvant Anastrozole Versus Tamoxifen in Patients Receiving Goserelin for Premenopausal Breast Cancer (STAGE): A Double-Blind, Randomised Phase 3 Trial
Neoadjuvant Anastrozole vs Tamoxifen With Goserelin in Early Breast Cancer
N Masuda, Y Sagara, T Kinoshita, S Noguchi, et al
20120020
2012 Jan 20
Lancet Oncol
Neoadjuvant Anastrozole Versus Tamoxifen in Patients Receiving Goserelin for Premenopausal Breast Cancer (STAGE): A Double-Blind, Randomised Phase 3 Trial
Lancet Oncol. 2012 Jan 20;[Epub Ahead of Print], N Masuda, Y Sagara, T Kinoshita, S Noguchi, et al
TAKE-HOME MESSAGE
Abstract
Abstract
Background: Aromatase inhibitors have shown increased efficacy compared with tamoxifen in postmenopausal early breast cancer. We aimed to assess the efficacy and safety of anastrozole versus tamoxifen in premenopausal women receiving goserelin for early breast cancer in the neoadjuvant setting.Methods: In this phase 3, randomised, double-blind, parallel-group, multicentre study, we enrolled premenopausal women with oestrogen receptor (ER)-positive, HER2-negative, operable breast cancer with WHO performance...
